The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population
BMC Urology volume 16, Article number: 60 (2016)
To investigate the relationship between depression and overactive bladder (OAB)/urinary incontinence symptoms among the clinical OAB population.
Patients who were diagnosed with overactive bladder (OAB) and age-matched control subjects without OAB were enrolled. Depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS-D). OAB/incontinence symptoms were assessed using the validated questionnaires: ICIQ-UI, ICIQ-OAB, UDI-6, IIQ-7, and OAB-q.
27.5 % of OAB patients in our study had depression (HADS ≥8), and 12 % of OAB patients had moderate to severe depression (HADS-D ≥11). OAB patients reported significantly higher HADS-D depression scores compared to age-matched controls (5.3 ± 3.9 versus 2.8 ± 3.9, p = 0.004). OAB patients with depression reported more severe incontinence symptoms (ICIQ-UI), greater bother and more impact on quality of life (UDI-6, IIQ-7) compared to OAB patients without depression (p = 0.001, 0.01, <0.001, respectively). However there were no differences in ICIQ-OAB and OAB-q. Among OAB patients, there were positive correlations between the severity of depression symptoms and OAB/incontinence symptoms (p-values <0.001 to 0.035).
27.5 % of OAB patients have depression. OAB patients with depression reported more severe urinary incontinence symptoms, greater bother and more impact on quality of life compared to those without depression. Future studies are needed to further examine the mechanistic links between depression and OAB/urinary incontinence.
Overactive bladder (OAB) affects up to 1 in 6 adult men and women in the United States . The syndrome is characterized by urinary urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other identifiable causes . Given the symptom bother and impact on quality of life, it is anticipated that many OAB patients would have psychosocial difficulties. A recent review suggested that depression might be associated with OAB . However most of the published studies were population-based epidemiological surveys. Surprisingly there was been very few papers that focused on OAB patients who presented to clinics [4–8].
Chiara et al.  compared the depression scores between female patients with stress incontinence, urgency incontinence, and mixed incontinence, and showed no differences in the depression scores between the three groups. In contrast, Stach-Lempinen et al.  showed that the odds of depression was significantly higher in female patients with urgency incontinence compared to those with stress incontinence (OR 3.7, 95 % CI 1.30-10.49, p = 0.026). Melville et al.  also showed that the odds of depression was higher in female patients with urgency incontinence or mixed incontinence compared to stress incontinence (OR 9.2-11.5). None of the studies above recruited a control group. In the only paper that recruited a control group, Zorn et al.  showed that patients with idiopathic urgency incontinence reported higher depression scores than controls who did not have incontinence. Overall the results of the studies were inconclusive.
A few studies have compared urinary incontinence (UI) patients with depression versus UI patients without depression. Melville et al.  showed that there was no difference in the daily UI episodes or the percent with moderate/large UI between UI patients with depression versus those without depression. Sung et al.  studied female obese UI patients, and also showed that there was no difference in the numbers of urgency incontinence episodes between obese UI patients with depression versus obese UI patients without depression. However, two other studies have reported higher Urogenital Distress Inventory (UDI) scores among UI patients with depression [4, 5].
It is evident that the few publications that have studied the clinical UI population yielded conflicting results [4–8]. All of the studies have recruited patients with a myriad of UI symptoms (stress, urgency, and mixed incontinence) or causes (idiopathic, obstructive, and neurogenic incontinence), thus the relationship between depression and OAB may be confounded. Most studies have examined urinary incontinence (UI) in general but have not focused on OAB specifically. To our knowledge none of the studies have specifically recruited OAB patients, compared OAB patients with versus without depression, and have correlated the severity of their depression and OAB symptoms.
Here we address the gap in the literature by specifically investigating the relationship between depression and OAB in the clinical OAB population. We have: (1) recruited OAB patients and age-matched controls, (2) compared their depression symptoms, (3) compared OAB patients with versus without depression, and (4) performed correlation analyses between the severity of their depression and OAB/incontinence symptoms.
Between October 2012 and July 2014, adult patients, aged 18 or above, diagnosed with OAB and age-matched controls without OAB were recruited into this study that inquired their depression and urinary symptoms. For OAB, patients must complain of urinary urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other identifiable causes, in accordance with the 2002 ICS (International Continence Society) definition of OAB . The clinical evaluation was performed by one clinician (HL) and followed the published AUA guidelines . Subjects with a history of urinary incontinence surgery, prostate surgery, urethral stricture disease, neurogenic bladder, urinary retention, pelvic radiation, tuberculosis cystitis, cyclophosphamide cystitis, genitourinary cancer, urinary stones, a documented positive urine culture in the past 6 weeks, or a post-void residual volume ≥150 mL were not eligible. Controls were recruited by local advertisement and research database. Controls must have no prior diagnosis of OAB or interstitial cystitis/bladder pain syndrome, no significant lower urinary tract symptoms (AUA symptom index < 7), no bladder or pelvic pain, and no evidence of urinary infection. Controls were age-matched to the OAB cohort. Age matching was operationalized by recruiting similar percentages of patients and controls in the following age bins: <35, 35–49, and ≥50 years old. All subjects signed an informed consent. The Washington University School of Medicine Institutional Review Board approved this study.
Depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) . The questionnaire contains 7 items to assess depression symptoms (HADS-D) and 7 items to assess anxiety symptoms (HADS-A). A score of ≥8 on the HADS-D was used to operationalize the presence of depression . We have also used a cut-offs of HADS-D 8–10 to indicate mild depression and ≥11 for moderate/severe depression. The developers of the HADS have recommended these cut-off points for mild (8–10), moderate (11–14), and severe (15–21) depression [10, 11]. To quantify the severity of depression symptoms, we have analyzed the HADS-D data as a continuous variable.
OAB/incontinence symptoms were assessed using the following validated questionnaires: 1) International Consultation on Incontinence – Urinary Incontinence Short Form (ICIQ-UI) , 2) International Consultation on Incontinence – Overactive Bladder (ICIQ-OAB) , 3) OAB-q Short Form , 4) Urogenital Distress Inventory Short Form (UDI-6) , and 5) Incontinence Impact Questionnaire Short Form (IIQ-7) . Briefly, ICIQ-UI is a 4-item questionnaire that assesses the frequency, amount and interference of urinary incontinence. ICIQ-OAB is a 4-item questionnaire that inquires about daytime frequency, nighttime frequency, urgency, and urgency incontinence. OAB-q contains two sub-scales that assess symptom bother and condition-specific quality of life. UDI-6 and IIQ-7 measure urinary distress and incontinence impact.
Linear regression models (continuous variables) were used for multivariate comparisons between OAB and controls, and between the OAB subgroups (with versus without depression), adjusting for age (continuous variable) and sex. Other potential covariates were not included in the models due to the given sample size. Spearman’s correlation was used for correlation analyses. p < 0.05 was considered significant difference. Data were presented as mean ± SD in the tables. All statistical analysis was completed using the open source statistical package R v3.2.0.
Fifty-one adult OAB patients and 30 age-matched controls participated in this study. Appendix 1 described the study population (demographics, urinary symptoms, validated questionnaires, and medical comorbidities). The mean age (± SD) of the OAB and the control groups was 53.8 ± 11.9 and 54.2 ± 12.3, respectively. There was no significant age or sex difference between the two groups (p = 0.984 and 0.14). As expected, OAB patients had worse OAB/incontinence symptoms and quality of life compared to controls.
Depression symptoms among OAB patients, and comparison to controls
OAB patients reported significantly higher depression scores than controls on the HADS-D (5.3 ± 3.9 versus 2.8 ± 3.9, p = 0.004, Table 1). The HADS-D scores were almost 90 % higher in OAB patients compared to controls. Looking at the individual items on the HADS-D scale, OAB patients fared worse compared to controls on the following items: “I still enjoy the things I used to enjoy;” “I can laugh and see the funny side of things;” “I feel as if I am slowed down;” and “I look forward to enjoyment to things.” (p = 0.044, 0.025, <0.001, 0.03, respectively). 27.5 % of OAB patients reported a HADS-D score ≥8, a threshold commonly used to indicate clinically relevant depression symptoms. 11.8 % OAB patients reported a HADS-D score ≥11, indicating moderate to severe depression symptoms. 32 % of OAB patients reported a medical history of depression.
Comparison of OAB patients with versus without depression symptoms
The OAB patients were categorized into two subgroups: those with depression (HADS-D score ≥8, 27.5 %) versus those without depression (HADS-D <8, 72.5 %). Their OAB/incontinence symptoms and quality of life were then compared between the two OAB subgroups. As shown in Table 2, OAB patients with depression reported more severe incontinence symptoms (ICIQ-UI), greater bother and more impact on quality of life (UDI-6, IIQ-7) compared to OAB patients without depression (p = 0.001, 0.01, <0.001, respectively). However there were no differences in ICIQ-OAB and OAB-q. The box plots of their ICIQ-UI, UDI-6 and IIQ-7 scores were presented in Fig. 1.
Since most of the validated urinary questionnaires assess multiple urinary symptoms and presented the results as composite scores, we performed an exploratory analysis to compare the difference in individual urinary symptoms between OAB patients with and without depression (Table 3). The results suggested that that depression was correlated with urinary incontinence or urgency incontinence symptoms (ICIQ-UI questions 3, 4, and ICIQ-OAB question 6a). However, the differences in urgency, frequency, and nocturia symptoms did not meet criteria for significance (p > 0.05).
Correlation between the severity of depression symptoms and OAB/incontinence symptoms
To quantify the severity of depression symptoms, we have analyzed the HADS-D data as a continuous variable (0 to 21). We then performed Spearman’s correlation analyses between HADS-D and the urinary questionnaires (Table 4). Among OAB patients, there were positive correlations between the severity of depression symptoms (HADS-D) and the severity of OAB/incontinence symptoms, symptom bother and impact on quality of life (ICIQ-UI, ICIQ-OAB, UDI-6, IIQ-7, OAB-q, p-values <0.001 to 0.035). The highest correlations were between HADS-D and IIQ-7, and between HADS-D and OAB-q quality of life (correlation coefficient = 0.53 and 0.40 respectively, p-values <0.001 and = 0.001 respectively).
The present study specifically recruited OAB patients. We compared the depression symptoms between OAB and controls, and the urinary symptoms between the two OAB subgroups – with and without depression. The results showed that: (1) OAB patients have higher depression scores than controls; (2) OAB patients with depression reported more severe incontinence, greater bother and more impact on quality of life than OAB patients without depression; (3) there are positive correlations between the severity of depression symptoms and OAB/incontinence symptoms among the OAB patients.
27.5 % of OAB patients in our study have depression symptoms based on the HADS-D scale (HADS-D ≥8). Moreover, more than 10 % of OAB patients in our study have moderate to severe depression (HADS-D ≥11). The high prevalence of depression in the clinical OAB population has therapeutic implications. Behaviors associated with depression may impede response to clinical intervention. For example, behavioral therapies for OAB (e.g., bladder training, dietary and fluid modification, pelvic floor muscle exercises) require active participation of the patient. Depressed patients may lack the self-motivation, desire, and persistent effort necessary to have a successful outcome with behavioral therapies. Depression may also influence compliance to pharmacological therapies. Since the goals of OAB treatment are not only to improve symptoms but also to improve quality of life and function, not recognizing depression and its impact may contribute to suboptimal improvement in patient’s global impression of improvement (PGI-I). Urologists or urogynecologists are usually not trained to diagnose and treat clinical depression. However, they can screen OAB patients, particularly those with severe urinary incontinence, for depressive symptoms using the HADS-D scale. HADS-D takes less than a minute for patients to complete. OAB patients that are flagged for depressive symptoms might be considered for referral. It is important to recognize psychosocial comorbidities in patients seeking care because of their potential influence on therapeutics and high prevalence (~30 % of OAB patients have depression, and >10 % have moderate to severe depression).
We have demonstrated the positive associations between the severity of depression symptoms and OAB/incontinence symptoms in this cross-sectional study. However, to the best of our knowledge, the nature behind this association is unknown. It is unclear which came first, the “chicken” or the “egg.” While it is not hard to imagine that the symptoms and functional impairment associated with OAB/incontinence may lead to depression, the possibility that OAB and depression may share a common pathophysiological pathway in some patients deserves further research. Selective serotonin uptake inhibitors are commonly used to manage depression. Reduction of serotonin levels in the central nervous system is associated with increased urinary frequency and bladder contractions, while activation of the central serotonergic system with a 5-HT uptake inhibitor depresses bladder contractions and increases the micturition threshold volume in animal studies . Thus depression may be mechanistically linked to OAB via the serotonergic pathway. In an earlier clinical study, duloxetine – a serotonin noradrenergic uptake inhibitor – has been shown to improve both the “wet” and “dry” symptoms in OAB patients .
A few population-based cohort studies have tried to clarify the relationship between depression and OAB. In an one-year longitudinal study of women aged 40 years and over, incident cases of depression was predicted by the presence of urgency incontinence at baseline; while incident cases of urgency incontinence was not predicted by depression at baseline . In two longitudinal studies involving older patients aged 65 and above, depression at baseline predicted new onset urgency incontinence at the 1-year follow up in one study and at the 6-year follow up in the second study [19, 20]. Studies in the clinical OAB population showed that depression improved with successful treatment of OAB with anticholinergic medications, botulinum toxin A, and InterStim neuromodulation [21–23]. Collectively these studies suggested a causality relationship between depression and OAB/incontinence. Future studies are needed to further examine the mechanistic links between depression and OAB.
It is interesting to note that in Table 2, we demonstrated differences in ICIQ-UI, UDI-6 and IIQ-7 but not in ICIQ-OAB or OAB-q between OAB patients with and without depression. As shown in Table 3, the main difference between OAB patients with and without depression was due to their incontinence rather than their urgency or frequency symptoms. Thus questionnaires that focus more on the incontinence symptoms (ICIQ-UI, UDI-6 or IIQ-7) captured the differences while questionnaires that focus more on urgency/frequency symptoms (OAB-q or ICIQ-OAB) may not have captured a difference.
The current study has limitations: 1) It was a single-institution study with small sample size, thus it may not have sufficient power for more detailed analyses (e.g., adjusting for additional potential covariates such as medical comorbidities in the multivariate analysis); 2) findings from patients seeking care at a tertiary medical center because of the severity of their symptoms may not be generalizable to the general OAB population; and 3) assessment of depression was based on self-reported symptoms. Although the HADS-D is commonly used to screen for depression in the outpatient setting, it is not a diagnostic tool for clinical depression, and it cannot be ascertained without psychiatric evaluation which was not performed here. Despite these limitations, many of the comparisons clearly demonstrated differences. Large multi-institutional studies of the clinical OAB population are needed to further examine these relationships.
About 30 % of OAB patients have depression. OAB patients with depression reported more severe urinary incontinence symptoms, greater bother and more impact on quality of life compared to those without depression. Future studies are needed to further examine the mechanistic links between depression and OAB/urinary incontinence.
Hospital anxiety and depression scale – depression subscale
International consultation on incontinence – overactive bladder
International consultation on incontinence – urinary incontinence short form
Incontinence impact questionnaire short form
Urogenital Distress Inventory Short Form
Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167.
Vrijens D, Drossaerts J, van Koeveringe G, et al. Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res. 2015;78:95.
Melville JL, Walker E, Katon W, et al. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence. Am J Obstet Gynecol. 2002;187:80.
Sung VW, West DS, Hernandez AL, et al. Association between urinary incontinence and depressive symptoms in overweight and obese women. Am J Obstet Gynecol. 2009;200:557 e1.
Chiara G, Piccioni V, Perino M, et al. Psychological investigation in female patients suffering from urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 1998;9:73.
Stach-Lempinen B, Hakala AL, Laippala P, et al. Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn. 2003;22:563.
Zorn BH, Montgomery H, Pieper K, et al. Urinary incontinence and depression. J Urol. 1999;162:82.
Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361.
Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res. 1997;42:17.
Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23:322.
Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol. 1996;77:805.
Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563.
Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn. 1995;14:131.
de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology. 2002;59:30.
Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int. 2007;100:337.
Perry S, McGrother CW, Turner K, et al. An investigation of the relationship between anxiety and depression and urge incontinence in women: development of a psychological model. Br J Health Psychol. 2006;11:463.
Nuotio M, Luukkaala T, Tammela TL, et al. Six-year follow-up and predictors of urgency-associated urinary incontinence and bowel symptoms among the oldest old: a population-based study. Arch Gerontol Geriatr. 2009;49:e85.
Hirayama A, Torimoto K, Mastusita C, et al. Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. Urology. 2012;80:71.
Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health. 2015;19:217.
Levin PJ, Siddiqui NY, Wu JM, et al. Psychosocial factors related to the use of InterStim(R) for the treatment of refractory overactive bladder. Female Pelvic Med Reconstr Surg. 2014;20:272.
Game X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int. 2011;107:1786.
We would like to thank all the subjects who participated in the study, Vivien Gardner for recruiting the subjects and performance of the study, Aleksandra Klim for IRB and study support, and Alethea Paradis for data management.
The study is funded by the National Institutes of Health, grant numbers P20-DK-097798 and K08-DK-094964. The funding body does not participate in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.
HL contributed to the conception, design, analysis and interpretation of the data. In addition, HL also drafted the manuscript, and agreed to be accountable for the accuracy and all other aspects of the work. BS and AR contributed to data analysis, literature review, and revision of the manuscript. JV contributed to the statistical analysis and interpretation of the data, design and construction of the database, data entry and management, revised the manuscript critically, and agreed to be accountable for the accuracy of the statistical analysis. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All subjects signed an informed consent. The Washington University School of Medicine Institutional Review Board approved this study. The IRB approval number is 201208077.
About this article
Cite this article
Lai, H., Shen, B., Rawal, A. et al. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol 16, 60 (2016). https://doi.org/10.1186/s12894-016-0179-x